COMMUNITY-DRIVEN DEVELOPMENT OF A MODIFIED PROGRESSION-FREE SURVIVAL RATIO FOR PRECISION ONCOLOGY

Objective Measuring the success of molecularly guided therapies is a major challenge in precision oncology trials.A commonly used endpoint is an intra-patient progression-free survival (PFS) ratio, defined as the PFS interval associated with molecularly guided therapy (PFS2) divided by the PFS interval associated with the last prior systemic therap

Chronic thromboembolic pulmonary hypertension (CTEPH) is a life-threatening condition in which organised thrombi obstruct the pulmonary vessels, causing increased pulmonary vascular resistance, progressive pulmonary hypertension (PH) and right heart failure.The treatment of choice is pulmonary endarterectomy, which restores pulmonary haemodynamics